Transcriptome, Proteome, and Metabolome in Dyssynchronous Heart Failure and CRT

[1]  H. Yoshimatsu,et al.  Effect of Cardiac Resynchronization Therapy on Cardiac Sympathetic Nervous Dysfunction and Serum C‐reactive Protein Level , 2011, Pacing and clinical electrophysiology : PACE.

[2]  G. Tomaselli,et al.  Reciprocal Transcriptional Regulation of Metabolic and Signaling Pathways Correlates With Disease Severity in Heart Failure , 2011, Circulation. Cardiovascular genetics.

[3]  Brian O'Rourke,et al.  Redox Regulation of Mitochondrial ATP Synthase: Implications for Cardiac Resynchronization Therapy , 2011, Circulation Research.

[4]  Peng-Sheng Chen,et al.  Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure , 2011, Journal of Interventional Cardiac Electrophysiology.

[5]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[6]  S. Solomon,et al.  Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial--Cardiac Resynchronization Therapy (MADIT-CRT). , 2010, Heart rhythm.

[7]  T. Arias,et al.  Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. , 2010, Cardiovascular research.

[8]  Neema Jamshidi,et al.  Assessment of Metabolic Phenotypes in Patients with Non-ischemic Dilated Cardiomyopathy Undergoing Cardiac Resynchronization Therapy , 2010, Journal of cardiovascular translational research.

[9]  D. Tamborero,et al.  Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy , 2010, European journal of heart failure.

[10]  D. Kass,et al.  Modulation of Mitochondrial Proteome and Improved Mitochondrial Function by Biventricular Pacing of Dyssynchronous Failing Hearts , 2010, Circulation. Cardiovascular genetics.

[11]  D. Kass,et al.  Mechanisms of Enhanced &bgr;-Adrenergic Reserve From Cardiac Resynchronization Therapy , 2009, Circulation.

[12]  Brian O'Rourke,et al.  Electrophysiological Consequences of Dyssynchronous Heart Failure and Its Restoration by Resynchronization Therapy , 2009, Circulation.

[13]  D. Kass,et al.  Cardiac Resynchronization Therapy Corrects Dyssynchrony-Induced Regional Gene Expression Changes on a Genomic Level , 2008, Circulation: Cardiovascular Genetics.

[14]  Antti Tanskanen,et al.  Key pathways associated with heart failure development revealed by gene networks correlated with cardiac remodeling. , 2008, Physiological genomics.

[15]  J. Kline,et al.  Role of inflammation in right ventricular damage and repair following experimental pulmonary embolism in rats , 2008, International journal of experimental pathology.

[16]  Jeroen J. Bax,et al.  Myocardial collagen metabolism in failing hearts before and during cardiac resynchronization therapy , 2008, European journal of heart failure.

[17]  J. Kline,et al.  Transcriptional profile of right ventricular tissue during acute pulmonary embolism in rats. , 2008, Physiological genomics.

[18]  G. Boriani,et al.  Effects of cardiac resynchronization therapy on coronary blood flow: Evaluation by transthoracic Doppler echocardiography ☆ , 2008, European journal of heart failure.

[19]  D. Kass,et al.  Reversal of Global Apoptosis and Regional Stress Kinase Activation by Cardiac Resynchronization , 2008, Circulation.

[20]  W. Wijns,et al.  Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. , 2008, Journal of the American College of Cardiology.

[21]  Arantxa González,et al.  Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. , 2007, European heart journal.

[22]  Jeroen J. Bax,et al.  Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin‐C and plasma matrix metalloproteinase‐9 levels , 2007, European journal of heart failure.

[23]  Theo Arts,et al.  Cardiac resynchronization therapy cures dyssynchronopathy in canine left bundle-branch block hearts. , 2007, European heart journal.

[24]  M. Volpe,et al.  Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin , 2007, European journal of heart failure.

[25]  D. Kass,et al.  Role of oxidative stress in cardiac hypertrophy and remodeling. , 2007, Hypertension.

[26]  K. Lappegård,et al.  Anti‐Inflammatory Effect of Cardiac Resynchronization Therapy , 2006, Pacing and clinical electrophysiology : PACE.

[27]  K. Margulies,et al.  Mixed Messages: Transcription Patterns in Failing and Recovering Human Myocardium , 2005, Circulation research.

[28]  Theo Arts,et al.  Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. , 2005, European heart journal.

[29]  Michel Haïssaguerre,et al.  Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. , 2004, Journal of the American College of Cardiology.

[30]  B. Nowak,et al.  Cardiac resynchronization therapyhomogenizes myocardial glucosemetabolism and perfusion in dilatedcardiomyopathy and left bundle branch block , 2003 .

[31]  B. Nowak,et al.  Cardiac resynchronization therapy homogenizes myocardial glucose metabolism and perfusion in dilated cardiomyopathy and left bundle branch block. , 2003, Journal of the American College of Cardiology.

[32]  Luigi Tavazzi,et al.  Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. , 2002, American heart journal.

[33]  R. Califf,et al.  Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). , 1999, American heart journal.

[34]  R. Walsh,et al.  Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. , 1998, Journal of molecular and cellular cardiology.

[35]  M. Packer,et al.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.